Sunday, November 8, 2026

GBP/EUR Jumps By 1% In The Last 21 Sessions

GBP/EUR Jumps By 1% In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.54% for the last 21 sessions. At 11:12 EST on Tuesday, 16 May, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 6.335% up from its 52-week low and 4.095% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.08%, 0.14%, and 0.27%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.27% (last week), 0.26% (last month), and 0.27% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy price analysis: snaps two-day uptrned near 136.00 on breaking immediate support. According to FXStreet on Tuesday, 16 May, "With this, the USD/JPY pair appears all set to test the 50% Fibonacci retracement level of its April 26 to May 02 upside, near 135.40.", "Following that, the 134.00 round figure and the monthly low of around 133.50 will gain the USD/JPY seller's attention."
  • Usd/jpy technical analysis: strengthening of bullish path - 15 May 2023. According to DailyForex on Monday, 15 May, "Technical analysis of the USD/JPY pair:In the near term, and according to the performance on the hourly chart, it appears that the USD/JPY is trading within a bullish channel formation.", "On the economic side, the USD/JPY currency pair is trading affected by the results of the latest economic data, as the Michigan Preliminary US Consumer Confidence Index for May missed the expected reading of 63 with a reading of 57.7. "
  • Usd/jpy price analysis: golden cross lures yen buyers to aim for 136.50. According to FXStreet on Monday, 15 May, "In a case where the Yen pair buyers ignore the aforementioned negatives to the USD/JPY bulls, the odds of witnessing a rally towards the previous monthly high of around 137.80 and the yearly top marked in March near 137.90, quickly followed by the 138.00 threshold, can't be ruled out.", "Meanwhile, a downside break of the stated HMAs, near 134.90-80, isn't an open invitation to the USD/JPY bears as an upward-sloping support line from April 26, close to 134.00, may act as the last defense of the buyers."
  • Usd/jpy bulls prod 136.00 amid firmer yields, US debt ceiling fears and dovish bias of boj’s ueda. According to FXStreet on Monday, 15 May, "Above all, concerns that the US may default in early June if the debt ceiling isn't altered soon seem to weigh on the market sentiment and underpin the US Dollar's run-up, fueling the USD/JPY in turn. ", "Looking forward, the US NY Empire State Manufacturing Index for May and Japan PM Kishida's orders will be eyed for immediate USD/JPY direction. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com